Evidence map›Paper›PMID 42094133›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Olfactory decline in aging: longitudinal trajectories and associations with cognitive decline and postmortem neuropathology.

Cecilia Tremblay, Parichita Choudhury, Erika Driver-Dunckley, Zaki Alasmar, Geidy E Serrano, Holly A Shill, Shyamal Mehta, Andrew Ho, Seyed-Mohammad Fereshtehnejad, David Shprecher and 7 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Cecilia TremblayCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada, H4H 1R3.ORCID 0000-0001-8460-7421
Parichita ChoudhuryCleo Roberts Center, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Erika Driver-DunckleyPacific Parkinson's Research Centre (PPRC), Djavad Mowafaghian Centre for Brain Health, University of British Columbia; Vancouver, BC V6T 1Z4, Canada.
Zaki AlasmarCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada, H4H 1R3.
Geidy E SerranoDepartment of Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Holly A ShillDivision of Neurology, Faculty of Medicine, University of British Columbia; Vancouver, BC V6T 1Z4, Canada.
Shyamal MehtaPacific Parkinson's Research Centre (PPRC), Djavad Mowafaghian Centre for Brain Health, University of British Columbia; Vancouver, BC V6T 1Z4, Canada.
Andrew HoCleo Roberts Center, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Seyed-Mohammad FereshtehnejadDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet; 171 77 Stockholm, Sweden.
David ShprecherCleo Roberts Center, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Ileana LorenziniDepartment of Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Christine M BeldenCleo Roberts Center, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Alireza AtriCleo Roberts Center, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Charles H AdlerPacific Parkinson's Research Centre (PPRC), Djavad Mowafaghian Centre for Brain Health, University of British Columbia; Vancouver, BC V6T 1Z4, Canada.
Thomas G BeachDepartment of Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, 85351, USA.
Mahsa DadarCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada, H4H 1R3.
Yashar ZeighamiCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada, H4H 1R3.

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI ALIREZA ATRI · 2021 to 2026
$24.9M
National Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8M
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NINDS NIH HHS U24 NS072026
6 · The paper itself

Abstract

Importance: Decline in olfactory function may be used as a predictor of cognitive decline, to enhance early detection models, improve risk stratification, and enable early intervention. Objective: To assess the longitudinal association between olfactory decline, cognitive decline, and postmortem neuropathology. Design setting and participants: Retrospective longitudinal analysis with clinicopathological correlations of a prospective population-based cohort study using data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and its Brain and Body Donation Program. Participants included cognitively unimpaired individuals without parkinsonism that converted to mild cognitive impairment (MCI) and/or dementia or remained cognitively stable. Main Outcomes and Measures: longitudinal change in olfaction, neuropsychiatric symptoms, motor function and memory, conversion to MCI/dementia, postmortem neuropathology. Results: Over a mean follow-up period of 7.7 ± 5.4 years, out of 922 participants who were cognitively unimpaired at the first cognitive conference, 643 remained cognitively unimpaired, 279 converted to MCI, and 82 developed dementia. Of these, 633 individuals had at least 2 olfactory tests.Converters showed reduced olfactory function (t=-12.6, p <0.0001), faster progression in neuropsychiatric symptom burden (t=3.42, p < 0.001), and faster decline in memory (t= -7.33, p <0.0001) prior to conversion while no significant differences were observed in motor scores between converters and non-converters. Using ROC analysis, olfactory decline, increased neuropsychiatric symptom burden, as well as motor and memory decline predicted conversion to MCI with a consistent accuracy of ~ 70% up to 5 years before conversion, while UPSIT alone had an accuracy of ~ 60%. Longitudinal decline in olfaction was associated with a higher burden of a-synuclein (t= -8.21, p <0.0005), tau tangle (t= -2.66, p < 0.01) and amyloid plaque burden (t= -2.85, p < 0.005) and a faster decline over time was associated with a higher burden of tau (t=5.66, p<0.0001). Conclusions and Relevance: A reduction in olfactory identification ability is observed up to a decade prior to conversion to MCI and is associated with underlying burden of neuropathology markers, underscoring the value of incorporating olfactory testing in cognitively unimpaired individuals to identify those at-risk of future cognitive decline.

Identifiers

PMID42094133
PMCPMC13142601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.